Scienture Holdings, Inc. (SCNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scienture Holdings, Inc. (SCNX) has a cash flow conversion efficiency ratio of 0.000x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.18 Million) by net assets ($70.12 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scienture Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Scienture Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Scienture Holdings, Inc. total liabilities for a breakdown of total debt and financial obligations.
Scienture Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scienture Holdings, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nusa Palapa Gemilang PT Tbk
JK:NPGF
|
0.084x |
|
Temple Bar Investment Trust
LSE:TMPL
|
0.018x |
|
CSH Alliance Bhd
KLSE:7165
|
0.085x |
|
Oxford Nanopore Technologies Ltd
LSE:ONT
|
-0.040x |
|
Surgepays Inc
NASDAQ:SURG
|
0.723x |
|
Yorkton Equity Group Inc
V:YEG
|
0.029x |
|
TS Corp Preference Shares
KO:001795
|
0.061x |
|
Asuransi Dayin Mitra Tbk
JK:ASDM
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Scienture Holdings, Inc. (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scienture Holdings, Inc. from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see SCNX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.12 Billion | $-13.38 Billion | -0.191x | -5.79% |
| 2024-12-31 | $79.07 Million | $-14.27 Million | -0.180x | +95.60% |
| 2023-12-31 | $542.35K | $-2.23 Million | -4.103x | +10.09% |
| 2022-12-31 | $342.87K | $-1.56 Million | -4.563x | -570.44% |
| 2021-12-31 | $3.77 Million | $-2.57 Million | -0.681x | -166.73% |
| 2020-12-31 | $8.68 Million | $-2.21 Million | -0.255x | -845.21% |
| 2019-12-31 | $4.14 Million | $141.78K | 0.034x | -89.42% |
| 2018-12-31 | $844.67K | $273.39K | 0.324x | +158.81% |
| 2017-12-31 | $-311.93K | $171.67K | -0.550x | -148.11% |
| 2016-12-31 | $-1.15 Million | $-1.31 Million | 1.144x | +115.48% |
| 2015-12-31 | $267.02K | $-1.97 Million | -7.392x | -364.14% |
| 2014-12-31 | $668.44K | $-1.06 Million | -1.593x | +75.32% |
| 2013-12-31 | $130.87K | $-844.58K | -6.454x | -1200.16% |
| 2008-12-31 | $-48.01 Million | $-28.16 Million | 0.587x | -32.41% |
| 2007-12-31 | $-18.51K | $-16.07K | 0.868x | +234.87% |
| 2006-12-31 | $9.67K | $-6.22K | -0.644x | -- |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. Th… Read more